Acumen Pharmaceuticals shares are trading higher after the company presented biomarker data from the ACU193 Phase 1 INTERCEPT-AD trial at the International Conference on Alzheimer's and Parkinson's Diseases.
Author: Benzinga Newsdesk | March 08, 2024 09:52am